<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="u">
		<monograph id="1" status="active">
			<mono_name>undecylenic acid topical</mono_name>
			<section type="none" id="sidelem4x19">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>unoprostone ophthalmic</mono_name>
			<section type="none" id="sidelem4x26">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>ustekinumab (Rx)</mono_name>
			<info>
				<pronunciation>(us′te-kin′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x350">Stelara</tradename>
				</tradenames>
				<class type="func"> Immune response modifier, antipsoriatic agent</class>
				<class type="chem"> Monoclonal antibody</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x45">
				<sec_title>Action:</sec_title>
				<para>Interleukin (IL)-12, IL-23 antagonist, binds to an interleukin protein, decreases inflammation</para>
			</section>
			<section type="uses" id="sidelem4x50">
				<sec_title>Uses:</sec_title>
				<para>Plaque psoriasis, psoriatic arthritis</para>
			</section>
			<section type="contra" id="sidelem4x55">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, sepsis, active infections</para>
				<section type="none" id="sidelem4x60">
					<section type="none" id="sidelem4x61">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breast-feeding, children ≤18 yr, geriatric patients, surgery, TB, diabetes mellitus, immunosuppression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x66">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x69">
					<section type="none" id="sidelem4x70">
						<sec_title>Moderate to severe plaque psoriasis</sec_title>
						<section type="none" id="sidelem4x78">
							<label>•</label>
							<sec_title>Adult ≥100 kg and plaque psoriasis<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x78">
									<item>
										<label>•</label>
										<para> 90 mg, repeat in 4 wk, then 90 mg q12wk starting wk 16</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x85">
							<label>•</label>
							<sec_title>Adult without plaque psoriasis<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x85">
									<item>
										<label>•</label>
										<para> 45 mg, repeat in 4 wk, then 45 mg q12wk starting wk 16</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x89">
						<sec_title>Psoriatic arthritis (monotherapy or methotrexate combination)</sec_title>
						<section type="none" id="sidelem4x97">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x97">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 45 mg repeat subcut in 4 wk, then q12wk maintenance</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x101">
						<sec_title>Psoriatic arthritis with moderate to severe plaque psoriasis (monotherapy or methotrexate combination)</sec_title>
						<section type="none" id="sidelem4x109">
							<label>•</label>
							<sec_title>Adult ≥100 kg<route> Subcut</route></sec_title>
							<para>
								<list id="lidelem4x109">
									<item>
										<label>•</label>
										<para> 90 mg, repeat in 4 wk, then q12wk maintenance</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x113">
						<sec_title>Available forms:</sec_title>
						<para> Solutions for inj 45 mg/0.5 ml, 90 mg/ml single use</para>
					</section>
					<section type="none" id="sidelem4x118">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x122">
								<item>
									<label>•</label>
									<para>Visually inspect for particulate matter or discoloration; solution should be slightly yellow and may contain a few small translucent or white particles; do not use if discolored, cloudy, or if foreign particulate matter is present; do not shake</para>
								</item>
								<item>
									<label>•</label>
									<para>Use at 27-G, 0.5-inch needle</para>
								</item>
								<item>
									<label>•</label>
									<para>May be administered subcut into upper arm, abdomen, or thigh; rotate inj sites</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x138">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x141">
					<section type="none" id="sidelem4x142">
						<sec_title>CNS:</sec_title>
						<para> Headache, leukoencephalopathy, depression, dizziness</para>
					</section>
					<section type="none" id="sidelem4x147">
						<sec_title>HEMA:</sec_title>
						<para> Bleeding</para>
					</section>
					<section type="none" id="sidelem4x152">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Inj-site reaction,</emphasis> pruritus, skin irritation, erythema</para>
					</section>
					<section type="none" id="sidelem4x160">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serious infections, malignancies</emphasis></para>
					</section>
					<section type="none" id="sidelem4x167">
						<sec_title>MS:</sec_title>
						<para> Myalgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x172">
						<sec_title>RESP:</sec_title>
						<para> URI</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x177">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Maximum serum concentration: 13.5 days after a single 45 mg subcut dose, 7 days after a single 90 mg subcut dose; half-life 14.9-45.6 days</para>
			</section>
			<section type="interactions" id="sidelem4x182">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x186">
						<item>
							<label>•</label>
							<para>Do not give concurrently with vaccines; immunizations should be brought up to date before treatment</para>
						</item>
						<item>
							<label>•</label>
							<para>Avoid use with immunosuppressives</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x197">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x200">
					<section type="none" id="sidelem4x201">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x206">
								<item>
									<label>•</label>
									<para>Bring immunizations up to date before starting treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x211">
								<item>
									<label>•</label>
									<para>Infection: monitor for fever, sore throat, cough, do not use during active infections</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x220">
							<label>•</label>
							<sec_title>Malignancy<route> skin cancer may occur especially in older patients who have used ultraviolet treatments with immunosuppressants</route></sec_title>
						</section>
						<section type="none" id="sidelem4x226">
							<label>•</label>
							<sec_title>TB<route> TB testing should be done before starting treatment</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x229">
								<item>
									<label>•</label>
									<para>For inj-site pain, swelling</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x234">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x238">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased plaque psoriasis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x244">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x248">
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time to be effective, to use as prescribed</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to receive live vaccinations during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of possible infection (upper respiratory or other) or allergic reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>Injection techniques and disposable, not to reuse needles, syringes</para>
								</item>
								<item>
									<label>•</label>
									<para>That follow-up will be needed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>